CD274 and ovarian carcinoma: Checkpoint immunotherapy trials such as programmed cell death protein‐1/programmed death ligand‐1 (PD‐1/PD‐L1) inhibitor therapy seemed promising for ovarian cancer patients at the beginning of their treatments.